Development PipelineSGN-BB228

an investigational costimulatory bispecific molecule composed of a CD228-directed antibody and 4-1BB-directed Anticalin® proteins

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.